| Title |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
|
|---|---|
| Published in |
Lancet Oncology, September 2019
|
| DOI | 10.1016/s1470-2045(19)30420-6 |
| Pubmed ID | |
| Authors |
Mario Giuliano, Francesco Schettini, Carla Rognoni, Manuela Milani, Guy Jerusalem, Thomas Bachelot, Michelino De Laurentiis, Guglielmo Thomas, Pietro De Placido, Grazia Arpino, Sabino De Placido, Massimo Cristofanilli, Antonio Giordano, Fabio Puglisi, Barbara Pistilli, Aleix Prat, Lucia Del Mastro, Sergio Venturini, Daniele Generali |
X Demographics
The data shown below were collected from the profiles of 129 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 15 | 12% |
| Japan | 13 | 10% |
| United States | 13 | 10% |
| United Kingdom | 5 | 4% |
| Italy | 4 | 3% |
| Mexico | 3 | 2% |
| France | 2 | 2% |
| India | 2 | 2% |
| Colombia | 2 | 2% |
| Other | 17 | 13% |
| Unknown | 53 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 86 | 67% |
| Practitioners (doctors, other healthcare professionals) | 24 | 19% |
| Scientists | 17 | 13% |
| Science communicators (journalists, bloggers, editors) | 2 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 259 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 259 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 37 | 14% |
| Student > Ph. D. Student | 23 | 9% |
| Other | 20 | 8% |
| Student > Master | 17 | 7% |
| Student > Bachelor | 17 | 7% |
| Other | 46 | 18% |
| Unknown | 99 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 83 | 32% |
| Biochemistry, Genetics and Molecular Biology | 14 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 5% |
| Nursing and Health Professions | 8 | 3% |
| Agricultural and Biological Sciences | 5 | 2% |
| Other | 32 | 12% |
| Unknown | 104 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 104. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2022.
All research outputs
#406,127
of 25,462,162 outputs
Outputs from Lancet Oncology
#519
of 6,901 outputs
Outputs of similar age
#8,424
of 350,713 outputs
Outputs of similar age from Lancet Oncology
#17
of 129 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,901 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,713 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 129 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.